Viz.ai
AI-powered clinical decision support platform. Detects large vessel occlusion stroke, pulmonary embolism, and aortic disease from CT scans in seconds.
FDA ClearedCE MarkBreakthrough Device
Headquarters
San Francisco, CA
CEO
Chris Mansi
Founded
2016
Employees
500+
Sector
AI Diagnostics
Therapeutic Area
Neurology, Cardiology, Vascular
Stage
Series D
Total Funding
$252M
Regulatory Pipeline
Viz LVO Stroke Detection
De Novo · Class II · Feb 2021
Viz PE Pulmonary Embolism
510(k) · Class II · Jun 2023
Viz Aortic Disease Detection
510(k) · Class II · Nov 2023
Funding History
Seed
2017
$7M
Innovation Endeavors
Series A
2019
$21M
Greenoaks Capital
Series C
2021
$100M
Tiger Global, Insight Partners
Series D
2023
$100M
Transformation Capital
Clinical Trials
Viz ONE Platform Real-World
ActivePhase IV · US
Open Positions
ML Research Scientist
AI · San Francisco, CA
$200K-$280K+ $80K-$150K options
AI/MLMedical ImagingPyTorch
Clinical Applications Engineer
Clinical · Remote
$120K-$150K+ $30K-$60K options
DICOMRadiologyIntegration